A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
Was this article valuable?
Here are more articles you may enjoy.
California Drought, Wildfire Risks Grow as Snow Falls Short 
Berkshire Hathaway to Invest $1.8 Billion in Tokio Marine 
LNG Supply Cut Further After Cyclone Hits Australian Plants 
Car Insurer First Central Is Said to Tap Banks for London IPO 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.